JAKARTA. PT Kalbe Farma Tbk (KLBF) established a new subsidiary, PT Kalbe Biotek Indonesia with an authorized capital of Rp 50 million, even though its debt rose by 37.96% in the first half of 2020.
Lukito Kurniawan Gozali, Corporate Secretary of KLBF, said that the company owns 99.23% of Kalbe Biotek shares. Meanwhile, the other 0.77% are owned by PT Bifarma Adiluhung, a subsidiary of KLBF that provides medical examination services.
However, KLBF management has not announced the sector Kalbe Biotek is engaged in.
According to idnfinancials.com data, KLBF's total liabilities were recorded at Rp 4.91 trillion at the end of the first semester of 2020. (KR/AR)